European Pharmaceutical Review
APRIL 10, 2025
In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030. There is worldwide concern around the use of PFAS.
pharmaphorum
NOVEMBER 23, 2020
The new, free of charge section makes tailored information about wet AMD available to the approximately 20 million people worldwide with wet AMD along with tools to help them stay on track with treatment and in communication with their doctors. The post Novartis taps smartpatient for app to support wet AMD patients appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 25, 2025
The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones. Sign up for our daily news round-up!
pharmaphorum
JANUARY 5, 2023
Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. Investing in technology for onboarding, training, and employee communication can help cut expenses and positively impact engagement.
European Pharmaceutical Review
MARCH 9, 2023
Based on the latest report and data, HPAPI market size is expected to reach $32 billion by 2028. The compounds require special handling due to their cytotoxicity in the NCEs and investigational new drug applications (INDs). 1 What are the challenges companies face in identifying and assessing the toxicity and potency of HPAPIs?
Pharmaceutical Technology
JUNE 20, 2023
With two of its upcoming drug launches already pipped to be blockbusters by 2028, smart manoeuvres in the immunology space could help Lilly close the gap between itself and other companies like Johnson & Johnson. Please check your email to download the Report.
Pharmaceutical Technology
JUNE 16, 2023
As it stands, GlobalData analysis predicts that Keytruda’s yearly revenue will hit almost $35bn in 2028, up from $21bn in 2022. It showed promising event-free survival (EFS) of 62.4% in the Keytruda arm, with median EFS not being met. Free Report How is the Biopharmaceutical industry evolving?
Expert insights. Personalized for you.
59 
Let's personalize your content